Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday

TLDR

• ARK Invest bought 112,815 shares of CRISPR Therapeutics for ~$5.63M across ARKK and ARKG ETFs
• ARK purchased 275,000 shares of PayPay Corp for ~$4.4M through its ARKF fintech ETF
• ARK also added GeneDx (~$4.43M) and Tempus AI (~$991K) to its portfolios
• On the sell side, ARK trimmed Teradyne (~$3.3M) and Ionis Pharmaceuticals (~$3.26M)
• ARK also reduced positions in 10x Genomics and Circle Internet Group

On March 12, 2026, Cathie Wood’s ARK Invest made over $10 million in purchases while cutting several existing positions, according to the firm’s daily trade disclosures.

The largest single buy of the day was CRISPR Therapeutics. ARK acquired 112,815 shares through two ETFs — the ARK Innovation ETF and the ARK Genomic Revolution ETF — for a combined total of roughly $5.63 million.

CRISPR Therapeutics AG, CRSP

CRISPR Therapeutics is a gene-editing biotech company. The purchase shows ARK’s continued belief in the long-term potential of genomic medicine.

ARK’s second biggest buy was PayPay Corp, a digital payments company. The firm picked up 275,000 shares through its ARK Fintech Innovation ETF for about $4.4 million.

PayPay Corp shares rose 13.50% on the day. The purchase adds to ARK’s existing focus on fintech and digital payment platforms.

ARK also added to positions in two other companies. It bought 52,075 shares of GeneDx, a genomic diagnostics company, for about $4.43 million. It also picked up 18,820 shares of Tempus AI, an AI healthcare data company, for roughly $991,000.

Where ARK Pulled Back

On the sell side, ARK sold 10,919 shares of Teradyne, a chip-testing equipment maker, through the ARK Innovation ETF for about $3.3 million. Teradyne shares fell 5.09% on the day.

This sale continues a recent pattern. ARK has been reducing its Teradyne position over several days.

ARK also sold 43,533 shares of Ionis Pharmaceuticals through its ARKG ETF for about $3.26 million. Ionis shares dropped 3.28% on the day.

The Ionis sale follows a broader trend of ARK pulling back from the RNA-based drug developer.

ARK trimmed two smaller positions as well. It sold 18,392 shares of 10x Genomics, a gene expression technology company, for about $376,000 across ARKK and ARKG.

It also sold 11,194 shares of Circle Internet Group, a stablecoin and blockchain payments company, via ARKK for about $1.26 million.

What Analysts Say

Analysts currently rate GeneDx and Ionis Pharmaceuticals as “Strong Buy.” GeneDx carries the highest upside potential of the group, at around 100%.

CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics all hold “Moderate Buy” ratings from analysts. PayPay Corp is rated “Hold.”

ARK also made a smaller purchase of 54,736 shares of Canton Strategic Holdings through its ARKF ETF, valued at about $254,522.

The post Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday appeared first on CoinCentral.